Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) have earned an average broker rating score of 1.50 (Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have assigned a strong buy rating to the company.
Brokerages have set a 1 year consensus price target of $9.95 for the company and are anticipating that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 185 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright set a $12.00 target price on DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 29th.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP purchased a new position in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) in the third quarter, according to its most recent filing with the SEC. The firm purchased 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned 1.69% of DelMar Pharmaceuticals at the end of the most recent quarter. 17.03% of the stock is currently owned by hedge funds and other institutional investors.
DelMar Pharmaceuticals (NASDAQ:DMPI) opened at $1.46 on Monday. The stock has a market capitalization of $31.54, a price-to-earnings ratio of -2.12 and a beta of 1.22. DelMar Pharmaceuticals has a 12-month low of $0.78 and a 12-month high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its earnings results on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01). equities analysts predict that DelMar Pharmaceuticals will post -0.54 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Average Recommendation of “Buy” by Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/05/zacks-delmar-pharmaceuticals-inc-dmpi-given-average-recommendation-of-buy-by-analysts.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.